# Ertapenem Administered Subcutaneously Versus Intravenously

> **NCT03218800** · PHASE3 · TERMINATED · sponsor: **Instituto Nacional de Cancer, Brazil** · enrollment: 30 (actual)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **COMBINATION_PRODUCT:** Ertapenem

## Key facts

- **NCT ID:** NCT03218800
- **Lead sponsor:** Instituto Nacional de Cancer, Brazil
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-06-01
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-02-28
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** not enough participants due to COVID19 pandemia
- **Last updated:** 2022-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03218800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03218800, "Ertapenem Administered Subcutaneously Versus Intravenously". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03218800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*